Shi Ming Tu

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
    S M Tu
    Department of Genitourinary Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Lancet 357:336-41. 2001
  2. ncbi Stem-cell origin of metastasis and heterogeneity in solid tumours
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 3:508-13. 2002
  3. ncbi Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2610-7. 2002
  4. ncbi Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:342-8. 2003
  5. ncbi Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
    Christos N Papandreou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3072-80. 2002
  6. ncbi Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2700-8. 2007
  7. ncbi Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1503-10. 2006
  8. ncbi Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2965-70. 2002
  9. ncbi Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:131-8. 2007
  10. ncbi A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2988-94. 2003

Detail Information

Publications49

  1. ncbi Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
    S M Tu
    Department of Genitourinary Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Lancet 357:336-41. 2001
    ..Prostate carcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted consolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate...
  2. ncbi Stem-cell origin of metastasis and heterogeneity in solid tumours
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 3:508-13. 2002
    ..Further investigation of the role of stem cells in the development of cancer may lead to the discovery of novel diagnostic tools, prognostic markers, and therapeutic targets in the battle against cancer...
  3. ncbi Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 94:2610-7. 2002
    ..Despite the proximity, prostate carcinoma seldom metastasizes to the penis or testis...
  4. ncbi Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 21:342-8. 2003
    ..Furthermore, the complicated dosing schedule and toxic effects of the regimen precluded its routine use in the treatment of urothelial carcinoma...
  5. ncbi Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate
    Christos N Papandreou
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3072-80. 2002
    ..To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa...
  6. ncbi Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2700-8. 2007
    ..The objective of the current study was to determine the clinical variables that predict this adverse outcome...
  7. ncbi Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1503-10. 2006
    ..The objective of this study was to determine whether the presence of viable tumor in the surgical specimen could be predicted...
  8. ncbi Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 20:2965-70. 2002
    ....
  9. ncbi Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:131-8. 2007
    ..We evaluated the recurrence pattern in patients with nonseminomatous germ cell tumors treated with post-chemotherapy retroperitoneal lymph node dissection and determined the optimal surveillance strategy in these patients...
  10. ncbi A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2988-94. 2003
    ..The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium-89 to patients with androgen independent prostate carcinoma...
  11. ncbi Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow
    Funda Vakar-Lopez
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pathol 203:688-95. 2004
    ..These observations indicate that MDA-BF-1 is up-regulated in metastatic PCa and raise the interesting possibility that MDA-BF-1 may play a role in the metastasis and progression of PCa, particularly in bone...
  12. ncbi Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 70:1173-8. 2007
    ....
  13. ncbi Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma
    Danai D Daliani
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:561-7. 2003
    ....
  14. ncbi Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib
    Paul Mathew
    Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 68:889-96. 2011
    ..Phase II study of tandutinib was conducted to assess the effects of a continuously administered highly potent PDGFR inhibitor in this disease state...
  15. ncbi Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7904-10. 2005
    ..We assessed the rate of bone marrow failure in patients with prostate cancer who had received a dose of strontium-89...
  16. ncbi Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level
    Dan Leibovici
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:198-204. 2007
    ..Occasionally, PC progression can occur despite low or undetectable PSA levels. The authors report on the clinical and pathologic characteristics of patients who experienced PC progression with undetectable or low PSA levels...
  17. ncbi Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer
    Sue Hwa Lin
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 14:3729-36. 2008
    ..We aimed to understand clinical implications of sErbB3 by establishing an ELISA to detect sErbB3 levels in bone marrow and plasma samples...
  18. ncbi Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases
    Alejandro Luina Contreras
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Hum Pathol 41:832-7. 2010
    ..Our findings suggest that the presence of an angiosarcomatous component in mediastinal germ cell tumor, even in a small amount, is associated with a poor clinical outcome...
  19. ncbi Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases
    Paul Mathew
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:5816-24. 2007
    ....
  20. ncbi Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study
    Jeri Kim
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Box 427, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:21-6. 2003
    ..8 to 17.1 months), with a 15.9-month median survival for 3 patients with poor performance status and visceral metastases. Further clinical investigation of the biological effect of IL-2 in urothelial carcinoma may be warranted...
  21. ncbi Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience
    Philippe E Spiess
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 177:1330-4; discussion 1334. 2007
    ..We defined the growth rate and reviewed our experience in the surgical management of growing teratoma syndrome in patients with nonseminomatous germ cell tumors...
  22. ncbi Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 8:341-51. 2010
    ....
  23. ncbi The central role of osteoblasts in the metastasis of prostate cancer
    Michel B Choueiri
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Metastasis Rev 25:601-9. 2006
    ..This review discusses the possible mechanisms of PCa bone metastasis and highlights the essential role of osteoblasts in the metastasis of PCa to bone...
  24. ncbi Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77239 1439, USA
    J Clin Oncol 27:3319-24. 2009
    ..We evaluated the safety and feasibility of a concurrent combination of weekly docetaxel with repeated (153)Sm-lexidronam in patients with castration-resistant prostate cancer (CRPC)...
  25. ncbi Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma
    George E Manoukian
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77230, USA
    Clin Genitourin Cancer 9:81-8. 2011
    ..This pilot trial evaluated the efficacy and safety of combining a bisphosphonate and a statin in patients with RCC metastatic to bone...
  26. ncbi Multisystem crisis in a patient with presumptive renal cell carcinoma
    Mehmet A Bilen
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Genitourin Cancer 6:128-30. 2008
    ..Prompt diagnosis and appropriate treatments could improve the performance status and quality of life of such patients...
  27. ncbi Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma
    Lance C Pagliaro
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Urol Oncol 24:487-91. 2006
    ..We conclude that single-agent capecitabine has minimal activity for the treatment of metastatic RCC...
  28. ncbi Current trials using bone-targeting agents in prostate cancer
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:35-9. 2008
    ..If so, targeting cancer stem cells or the onco-niche may offer another way to improve treatment of prostate cancer bone metastasis...
  29. ncbi Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy
    Bita Esmaeli
    Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:504-7. 2003
    ..The current study was conducted to report the severity and management of canalicular and nasolacrimal duct stenosis as a side effect of docetaxel therapy and to report the outcomes of surgical intervention for this condition...
  30. ncbi Patient survival after surgery for osseous metastases from renal cell carcinoma
    Patrick P Lin
    Department of Orthopaedic Oncology, The University of Texas M D Anderson Cancer Center, Unit 408, P O Box 301402, Houston, TX 77230, USA
    J Bone Joint Surg Am 89:1794-801. 2007
    ..The goal of this retrospective study was to evaluate factors that may affect survival after surgical treatment of metastases of renal cell carcinoma...
  31. ncbi Prostate cancer stem cells
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas, MD, Anderson Cancer Center, Houston, TX 77030 3721, USA
    Clin Genitourin Cancer 10:69-76. 2012
    ..Ultimately, the stem cell theory of cancers will affect how we practice clinical oncology: our diagnosis, monitoring, and therapy of prostate and other cancers...
  32. ncbi Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection
    Robert S Svatek
    Department of Urologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1310-7. 2009
    ....
  33. ncbi Biology and clinical management of prostate cancer bone metastasis
    Xiang cang Ye
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Front Biosci 12:3273-86. 2007
    ....
  34. ncbi Multilocular cystadenoma and cystadenocarcinoma of the prostate
    Tomasz Tuziak
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 25:19-25. 2007
    ..Multicystic prostatic tumors are rare, with only a few reported cases of prostatic cystadenoma and cystadenocarcinoma in the scientific literature...
  35. ncbi Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy
    Shi Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:2872-80. 2009
    ..The authors of this report investigated the clinical outcome of patients who had prostate ductal adenocarcinoma after primary radical prostatectomy or radiotherapy...
  36. ncbi Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
    ....
  37. ncbi Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases
    Charles C Guo
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Am J Surg Pathol 33:1173-8. 2009
    ..However, patients with a SC in the metastasis have an increased risk of mortality...
  38. ncbi Recurrent seminomas: clinical features and biologic implications
    Avik Som
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 30:494-501. 2012
    ..We also wished to test whether these tumors expressed any specific biomarkers that might distinguish them as a unique subtype of seminoma...
  39. ncbi The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients
    Sriram Yennurajalingam
    Department of Palliative Care and Rehabilitation Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Palliat Med 15:20-4. 2012
    ..The aim of this retrospective study was to describe the impact of an outpatient palliative care (PC) consultation on symptoms in patients with advanced prostate cancer...
  40. ncbi Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients
    Fernanda I Staquicini
    David H Koch Center
    Proc Natl Acad Sci U S A 108:18637-42. 2011
    ..These findings provide vascular molecular markers for biotechnology and medical applications...
  41. ncbi Surgical management of prostate cancer metastatic to the spine
    Brian J Williams
    Department of Neurosurgery, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Neurosurg Spine 10:414-22. 2009
    ..In this study, a series of patients undergoing spinal surgery for metastatic prostate cancer were reviewed to identify predictors of survival and functional outcome...
  42. ncbi Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ....
  43. ncbi Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
    Christos N Papandreou
    The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 0427, Houston, TX 77030, USA
    J Clin Oncol 22:2108-21. 2004
    ..This agent should be further explored with chemotherapy agents in advanced prostate cancer...
  44. ncbi Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    Shi-Ming Tu
    J Natl Cancer Inst 95:1174-5; author reply 1175. 2003
  45. ncbi Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1361-7. 2002
    ..Thus, FAP is very likely to be inferior to M-VAC and is certainly no less toxic. FAP cannot be recommended as part of the standard armamentarium for urothelial cancer...
  46. ncbi Targeting prostate cancer bone metastases
    Christopher Logothetis
    Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 97:785-8. 2003
  47. ncbi Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer
    Philippe E Spiess
    Department of Urologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1483-90. 2006
    ..Advanced clinical stage and viable tumor in the surgical specimen predict worse RFS...
  48. ncbi Clinical aspects of bone metastases in prostate cancer
    Shi-Ming Tu
    Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Treat Res 118:23-46. 2004
  49. ncbi Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells
    Chien Jui Cheng
    Department of Pathology, Taipei Medical University and Hospital, Taipei, Taiwan
    Mol Cancer Res 5:675-84. 2007
    ..We speculate that nuclear localization of ErbB-3 may aid prostate cancer cell survival during androgen ablation and progression of prostate cancer in bone...